Teligent (TLGT) Earning Favorable Media Coverage, Study Shows
News headlines about Teligent (NASDAQ:TLGT) have been trending positive recently, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Teligent earned a media sentiment score of 0.32 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.2468043426375 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Teligent (TLGT) traded up $0.01 during trading on Friday, reaching $3.14. 1,300,000 shares of the company were exchanged, compared to its average volume of 517,426. The company has a quick ratio of 2.71, a current ratio of 3.28 and a debt-to-equity ratio of 2.23. The company has a market cap of $168.21, a price-to-earnings ratio of -14.27, a PEG ratio of 62.60 and a beta of 1.07. Teligent has a twelve month low of $2.75 and a twelve month high of $9.54.
TLGT has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Teligent from a “hold” rating to a “strong sell” rating in a report on Saturday, November 11th. Canaccord Genuity set a $4.00 target price on shares of Teligent and gave the stock a “hold” rating in a report on Saturday, December 9th. Finally, TheStreet lowered shares of Teligent from a “c-” rating to a “d+” rating in a report on Wednesday, November 1st. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $7.00.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.